Prosecution Insights
Last updated: October 04, 2026

Reistone Biopharma Company Limited

1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Reistone Biopharma Company Limited has 1 pending office action in its current patent portfolio. This matter is assigned to a distinct examiner, representing a singular point of contact for the company's active prosecution. This arrangement requires the company to focus its resources on a single set of examiner objections and procedural requirements.

JEAN-LOUIS, SAMIRA JM is the busiest examiner for the company, with 1 pending office action. This examiner is currently overseeing the only active office action for the portfolio. The company's immediate path to patent protection is defined by the interaction with this specific examiner regarding the outstanding matter.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

0
Life Sciences
0% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
100% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
JEAN-LOUIS, SAMIRA JM 1 61.0% +45.2%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18872171 POLYMORPH OF BENZO[C]CHROMAN COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF JEAN-LOUIS, SAMIRA JM —

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18872171 POLYMORPH OF BENZO[C]CHROMAN COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF JEAN-LOUIS, SAMIRA JM — §112 Non-Final OA — Pending Dec 05, 2024

Managing Reistone Biopharma Company Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month